Fremman Capital acquires Amethyst Healthcare to drive growth

UK – Fremman Capital has announced its acquisition of Amethyst Healthcare Group, one of Europe’s largest independent cancer care providers, from its founding shareholders and U.S. investment firm The Rohatyn Group (TRG).

This move is set to fuel Amethyst’s expansion in radiotherapy, a key treatment for cancer patients worldwide.

Founded in 2010, Amethyst operates 19 cancer treatment centers across France, Poland, Romania, the UK, Italy, and Austria, providing essential oncology services to over 50,000 patients annually.

With over 500 specialists and 40 advanced linear accelerators, the company is recognized for its cutting-edge radiotherapy solutions.

Strategic Growth & Market Expansion Fremman Capital aims to harness its global healthcare expertise to accelerate Amethyst’s development, with the goal of building a leading European radiotherapy provider.

“Amethyst fits perfectly into our strategy of supporting market-leading providers of essential services,” said Edward Chandler, founding partner at Fremman Capital.

The radiotherapy sector is highly resilient, driven by the growing number of cancer cases and the increasing recognition of radiotherapy as a cost-effective, non-invasive treatment.

Experts predict strong market growth in the coming years, making this acquisition a timely investment.

TRG’s role & Amethyst’s expansion

TRG first invested in Amethyst in 2019, seeing potential in its ability to meet the rising demand for cancer care across Europe.

“During our ownership period, Amethyst transformed into a sizable business on a European scale,” noted Colin Clark, TRG’s partner & head of Europe.

At the time, Amethyst ran nine centers across five countries, treating 10,000 patients annually.

Since then, the company has expanded significantly, adding new centers in Austria, Italy, and the UK, alongside strategic acquisitions such as Medical Equipment Solutions Limited (MESL) in London and Sheffield.

In 2024, Amethyst secured €300 million in financing from Ares Management Corporation, enabling investments in advanced radiotherapy technologies and new treatment centers across Europe.

Looking ahead

With Fremman Capital now steering Amethyst’s next phase, the company is positioned for strong growth and continued innovation in cancer treatment.

This acquisition reinforces the broader trend of investment in high-quality, patient-focused oncology care, ensuring greater access to advanced radiotherapy solutions for patients across Europe.